Correlation Between Scopus Biopharma and Milestone Pharmaceuticals

Can any of the company-specific risk be diversified away by investing in both Scopus Biopharma and Milestone Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Scopus Biopharma and Milestone Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Scopus Biopharma and Milestone Pharmaceuticals, you can compare the effects of market volatilities on Scopus Biopharma and Milestone Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Scopus Biopharma with a short position of Milestone Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Scopus Biopharma and Milestone Pharmaceuticals.

Diversification Opportunities for Scopus Biopharma and Milestone Pharmaceuticals

0.39

Correlation Coefficient

Scopus Biopharma  Milestone Pharmaceuticals

Weak diversification

The 3 months correlation between Scopus and Milestone is 0.39. Overlapping area represents the amount of risk that can be diversified away by holding Scopus Biopharma and Milestone Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Milestone Pharmaceuticals and Scopus Biopharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Scopus Biopharma are associated (or correlated) with Milestone Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Milestone Pharmaceuticals has no effect on the direction of Scopus Biopharma i.e., Scopus Biopharma and Milestone Pharmaceuticals go up and down completely randomly.

Pair Corralation between Scopus Biopharma and Milestone Pharmaceuticals

If you would invest  198.00  in Milestone Pharmaceuticals on October 26, 2024 and sell it today you would earn a total of  1.00  from holding Milestone Pharmaceuticals or generate 0.51% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Very Weak
Accuracy	5.56%
Values	Daily Returns

Scopus Biopharma  vs.  Milestone Pharmaceuticals

Scopus Biopharma

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Scopus Biopharma has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable basic indicators, Scopus Biopharma is not utilizing all of its potentials. The recent stock price uproar, may contribute to short-horizon losses for the private investors.

Milestone Pharmaceuticals

Risk-Adjusted Performance

11 of 100

Good

Compared to the overall equity markets, risk-adjusted returns on investments in Milestone Pharmaceuticals are ranked lower than 11 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively unsteady basic indicators, Milestone Pharmaceuticals unveiled solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Scopus Biopharma and Milestone Pharmaceuticals

The main advantage of trading using opposite Scopus Biopharma and Milestone Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Scopus Biopharma position performs unexpectedly, Milestone Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Milestone Pharmaceuticals will offset losses from the drop in Milestone Pharmaceuticals' long position.

The idea behind Scopus Biopharma and Milestone Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.